Cancer Genetics Expands Market Share In Immuno-Oncology Focused Clinical Studies

By: via Benzinga
Cancer Genetics, Inc. (Nasdaq: CGIX) revealed it was actively testing and providing data for 12 Immuno-Oncology (IO) clinical trials ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.